Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4409 Target Snapshot

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
6,344Compounds
341Assays
4Approved Drugs
8,133.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9Y233. Start with Airway obstruction, then reuse UniProt Q9Y233 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Airway obstruction, then reuse UniProt Q9Y233 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Airway obstruction

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Airway obstruction because it currently carries approved-linked support. Linked drugs include IBUDILAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A as ChEMBL target CHEMBL4409, mapped to UniProt Q9Y233. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4409
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y233
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A is the right protein anchor across sources, using UniProt Q9Y233 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Airway obstruction is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamecAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ9Y233
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
UniProt AccessionQ9Y233
Component TypeProtein
Sequence Length1055 aa

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A, mapped to UniProt Q9Y233. Sequence length is 1055 aa.

Mapped IDQ9Y233
Review namecAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A shows approved-linked disease relevance led by Airway obstruction. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Airway obstruction
1 linked drug · 1 direct · 1 efficacy
Linked drugIBUDILAST
Late clinical Phase III
Myelopathy
1 linked drug · 1 direct · 1 efficacy
Linked drugIBUDILAST
Clinical signal Phase II
Huntington disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugMARDEPODECT
Linked drugPBF-999
Clinical signal Phase II
schizophrenia
2 linked drugs · 2 direct · 2 efficacy
Linked drugBALIPODECT
Linked drugMARDEPODECT
Clinical signal Phase II
alcohol dependence
1 linked drug · 1 direct · 1 efficacy
Linked drugIBUDILAST
Clinical signal Phase II
amyotrophic lateral sclerosis
1 linked drug · 1 direct · 1 efficacy
Linked drugIBUDILAST
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Airway obstruction because it currently carries approved-linked support. Linked drugs include IBUDILAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseAirway obstruction
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase III
7
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC506,743.0
KI1,367.0
KD23.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3686937 11.0 IC50 0.01 Preclinical
CHEMBL5897423 11.0 Ki 0.01 Preclinical
CHEMBL5795042 11.0 Ki 0.01 Preclinical
CHEMBL5874748 11.0 Ki 0.01 Preclinical
CHEMBL5856126 11.0 Ki 0.01 Preclinical
CHEMBL4111794 11.0 Ki 0.01 Preclinical
CHEMBL3960405 11.0 Ki 0.01 Preclinical
CHEMBL3746277 11.0 Ki 0.01 Preclinical
CHEMBL3746993 11.0 Ki 0.01 Preclinical
CHEMBL3745790 11.0 Ki 0.01 Preclinical
Distribution

pChEMBL Value Distribution

352
5.0
230
5.5
521
6.0
667
6.5
1019
7.0
963
7.5
1022
8.0
879
8.5
657
9.0
233
9.5
pChEMBL
Approved Drugs

Approved Drugs

VARDENAFIL
CHEMBL1520
Approved 2003
Properties Compare Identifier
DIPYRIDAMOLE
CHEMBL932
Approved 1961
Properties Compare Identifier
Assay Landscape

Assay Landscape

341
Total Assays
5,692
Tested Compounds
3
Assay Types
Binding — 330 assays, 5,692 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 229 3,445 7.8
cell-based format 64 1,192 7.3
assay format 36 1,036 7.8
subcellular format 1 19 9.3
ADME — 8 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 7 5.7
cell-based format 3 0 —
Functional — 3 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 3 8.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine